{"id":10441,"date":"2026-08-01T15:55:54","date_gmt":"2026-08-01T12:55:54","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=10441"},"modified":"2026-08-01T15:56:26","modified_gmt":"2026-08-01T12:56:26","slug":"bullet-sublingual-nitroglycerin-before-pre-tavi-ccta-scct-2026","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/bullet-sublingual-nitroglycerin-before-pre-tavi-ccta-scct-2026\/","title":{"rendered":"Bullet: Sublingual Nitroglycerin Before Pre-TAVI CCTA (SCCT 2026)"},"content":{"rendered":"<p>Bullet: Sublingual Nitroglycerin Before Pre-TAVI CCTA (SCCT 2026)<\/p>\n<p>Source: SCCT Annual Scientific Meeting 2026 (Presented July 2026).<\/p>\n<p>* Traditionally contraindicated in severe aortic stenosis (AS) because of concerns about hypotension.<br \/>\n* Prospective study (109 patients) found 0.8 mg sublingual nitroglycerin before pre-TAVI CCTA was safe and well tolerated in carefully selected patients.<br \/>\n* Significantly improved coronary artery image quality and visualization.<\/p>\n<p>* Associated with a 27% relative reduction in invasive coronary angiography (not statistically significant).<br \/>\n* Mean systolic BP decreased from 158 to 140 mmHg, without serious hemodynamic instability<br \/>\n* Patients with baseline hypotension, LVEF &lt;30%, critical AS, or other contraindications were excluded.<br \/>\n* Investigators concluded that routine use of sublingual nitroglycerin before pre-TAVI CTA may be appropriate in clinically stable patients with severe AS.<\/p>\n<p><a href=\"https:\/\/www.tctmd.com\/news\/sublingual-nitroglycerin-appears-safe-helpful-pre-tavi-ccta\">https:\/\/www.tctmd.com\/news\/sublingual-nitroglycerin-appears-safe-helpful-pre-tavi-ccta<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bullet: Sublingual Nitroglycerin Before Pre-TAVI CCTA (SCCT 2026) Source: SCCT Annual Scientific Meeting 2026 (Presented July 2026). * Traditionally contraindicated in severe aortic stenosis (AS) because of concerns about hypotension. * Prospective study (109 patients) found 0.8 mg sublingual nitroglycerin before pre-TAVI CCTA was safe and well tolerated in carefully selected patients. * Significantly improved [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10441","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=10441"}],"version-history":[{"count":2,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10441\/revisions"}],"predecessor-version":[{"id":10443,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10441\/revisions\/10443"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=10441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=10441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=10441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}